Literature DB >> 25311639

Novel approaches for targeting the adenosine A2A receptor.

Gengyang Yuan1, Nicholas G Gedeon, Tanner C Jankins, Graham B Jones.   

Abstract

INTRODUCTION: The adenosine A2A receptor (A2AR) represents a drug target for a wide spectrum of diseases. Approaches for targeting this membrane-bound protein have been greatly advanced by new stabilization techniques. The resulting X-ray crystal structures and subsequent analyses provide deep insight to the A2AR from both static and dynamic perspectives. Application of this, along with other biophysical methods combined with fragment-based drug design (FBDD), has become a standard approach in targeting A2AR. Complementarities of in silico screening based- and biophysical screening assisted- FBDD are likely to feature in future approaches in identifying novel ligands against this key receptor. AREAS COVERED: This review describes evolution of the above approaches for targeting A2AR and highlights key modulators identified. It includes a review of: adenosine receptor structures, homology modeling, X-ray structural analysis, rational drug design, biophysical methods, FBDD and in silico screening. EXPERT OPINION: As a drug target, the A2AR is attractive as its function plays a role in a wide spectrum of diseases including oncologic, inflammatory, Parkinson's and cardiovascular diseases. Although traditional approaches such as high-throughput screening and homology model-based virtual screening (VS) have played a role in targeting A2AR, numerous shortcomings have generally restricted their applications to specific ligand families. Using stabilization methods for crystallization, X-ray structures of A2AR have greatly accelerated drug discovery and influenced development of biophysical-in silico hybrid screening methods. Application of these new methods to other ARs and G-protein-coupled receptors is anticipated in the future.

Entities:  

Keywords:  X-ray crystal structures; adenosine A2A receptor; anti-Parkinson’s disease; biophysical methods; fragment-based drug design; homology modeling; inflammatory disease; virtual screening

Mesh:

Substances:

Year:  2014        PMID: 25311639     DOI: 10.1517/17460441.2015.971006

Source DB:  PubMed          Journal:  Expert Opin Drug Discov        ISSN: 1746-0441            Impact factor:   6.098


  4 in total

1.  Photoaffinity Labeling of the Human A2A Adenosine Receptor and Cross-link Position Analysis by Mass Spectrometry.

Authors:  Hideyuki Muranaka; Takaki Momose; Chiaki Handa; Tomonaga Ozawa
Journal:  ACS Med Chem Lett       Date:  2017-05-17       Impact factor: 4.345

2.  Fluorinated Adenosine A2A Receptor Antagonists Inspired by Preladenant as Potential Cancer Immunotherapeutics.

Authors:  Gengyang Yuan; Tanner C Jankins; Christopher G Patrick; Phaethon Philbrook; Olivia Sears; Stephen Hatfield; Michail Sitkovsky; Neil Vasdev; Steven H Liang; Mary Jo Ondrechen; Michael P Pollastri; Graham B Jones
Journal:  Int J Med Chem       Date:  2017-10-19

3.  Bitopic fluorescent antagonists of the A2A adenosine receptor based on pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine functionalized congeners.

Authors:  Romain Duroux; Antonella Ciancetta; Philip Mannes; Jinha Yu; Shireesha Boyapati; Elizabeth Gizewski; Said Yous; Francisco Ciruela; John A Auchampach; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Medchemcomm       Date:  2017-06-22       Impact factor: 3.597

4.  Structure-based identification of dual ligands at the A2AR and PDE10A with anti-proliferative effects in lung cancer cell-lines.

Authors:  Leen Kalash; Ian Winfield; Dewi Safitri; Marcel Bermudez; Sabrina Carvalho; Robert Glen; Graham Ladds; Andreas Bender
Journal:  J Cheminform       Date:  2021-03-03       Impact factor: 5.514

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.